Literature DB >> 31382822

Lipids, Apolipoproteins, and the Risk of Parkinson Disease.

Fang Fang1, Yiqiang Zhan1, Niklas Hammar2, Xia Shen1,3,4, Karin Wirdefeldt1,5, Göran Walldius2, Daniela Mariosa1.   

Abstract

RATIONALE: A complete picture of the associations of the most common lipid fractions, including total cholesterol (TC), LDL-C (low-density lipoprotein cholesterol), HDL-C (high-density lipoprotein cholesterol), triglycerides, and apolipoproteins, with the risk of Parkinson disease (PD), is lacking.
OBJECTIVE: To assess the associations of lipids and apolipoproteins with the future risk of PD. METHODS AND
RESULTS: In the AMORIS (Apolipoprotein-Related Mortality Risk) Study, we enrolled ≈600 000 participants during 1985 to 1996 in Stockholm, Sweden, with repeated measurements of TC, LDL-C, HDL-C, triglycerides, ApoB (apolipoprotein B), and ApoA-I (apolipoprotein A-I). The cohort was followed until the end of 2011, and incident cases of PD were identified through the Swedish Patient Register. We first used Cox models to estimate the associations of these biomarkers with later risk of PD. We further applied a Mendelian randomization analysis for TC, LDL-C, and triglycerides using the GWAS (Genome-wide association study) summary statistics from the public PD GWAS data and 23andMe PD cohorts with >800 000 individuals. One SD increase of TC was associated with a lower hazard of PD (hazard ratio, 0.90; 95% CI, 0.87-0.94). Similar associations were observed for LDL-C (hazard ratio, 0.93; 95% CI, 0.88-0.98), triglycerides (hazard ratio, 0.94; 95% CI, 0.90-0.97), and ApoB (hazard ratio, 0.91; 95% CI, 0.85-0.97). A clear dose-response relation was also noted when using these biomarkers as categorical variables. A causal inverse association of TC, LDL-C, and triglycerides with PD risk was further suggested by the Mendelian randomization analysis.
CONCLUSIONS: Our findings reinforce that higher levels of TC, LDL-C, and triglycerides are associated with a lower future risk of PD and further suggest that these associations may be causal. The findings for ApoB in relation to PD risk are novel, and whether such association is causal needs to be examined.

Entities:  

Keywords:  Parkinson disease; biomarkers; epidemiology; risk factors; triglycerides

Year:  2019        PMID: 31382822     DOI: 10.1161/CIRCRESAHA.119.314929

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  17 in total

1.  Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran.

Authors:  Samira Saedi; Mohsen Hemmati-Dinarvand; Haleh Barmaki; Zohreh Mokhtari; Hadis Musavi; Mohamad Valilo; Ali Mota; Soleiman Mahjoub
Journal:  Caspian J Intern Med       Date:  2021-03

2.  A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease.

Authors:  Xiaoxue Fu; Yu Wang; Xiaofeng He; Hongyu Li; Hong Liu; Xiangyang Zhang
Journal:  Lipids Health Dis       Date:  2020-05-19       Impact factor: 3.876

3.  ApoPred: Identification of Apolipoproteins and Their Subfamilies With Multifarious Features.

Authors:  Ting Liu; Jia-Mao Chen; Dan Zhang; Qian Zhang; Bowen Peng; Lei Xu; Hua Tang
Journal:  Front Cell Dev Biol       Date:  2021-01-08

4.  Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease.

Authors:  Zhu Liu; Qingli Fan; Shizheng Wu; Yaqi Wan; Yancheng Lei
Journal:  Lipids Health Dis       Date:  2021-04-19       Impact factor: 3.876

5.  Serum lipid profile among sporadic and familial forms of Parkinson's disease.

Authors:  Daniel Macías-García; María Teresa Periñán; Laura Muñoz-Delgado; María Valle Jimenez-Jaraba; Miguel Ángel Labrador-Espinosa; Silvia Jesús; Dolores Buiza-Rueda; Carlota Méndez-Del Barrio; Astrid Adarmes-Gómez; Pilar Gómez-Garre; Pablo Mir
Journal:  NPJ Parkinsons Dis       Date:  2021-07-16

6.  Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.

Authors:  Avner Thaler; Shani Shenhar-Tsarfaty; Yanay Shaked; Tanya Gurevich; Nurit Omer; Anat Bar-Shira; Mali Gana-Weisz; Orly Goldstein; Meir Kestenbaum; Jesse M Cedarbaum; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

7.  Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson's Disease Severity.

Authors:  Wanlin Yang; Zihan Chang; Rongfang Que; Guomei Weng; Bin Deng; Ting Wang; Zifeng Huang; Fen Xie; Xiaobo Wei; Qin Yang; Mengyan Li; Kefu Ma; Fengli Zhou; Beisha Tang; Vincent C T Mok; Shuzhen Zhu; Qing Wang
Journal:  Front Aging Neurosci       Date:  2020-03-06       Impact factor: 5.750

8.  Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.

Authors:  Dylan M Williams; Sara Bandres-Ciga; Karl Heilbron; David Hinds; Alastair J Noyce
Journal:  Ann Neurol       Date:  2020-09-07       Impact factor: 10.422

9.  Clinical Association between Gout and Parkinson's Disease: A Nationwide Population-Based Cohort Study in Korea.

Authors:  Ji Hyoun Kim; In Ah Choi; Aryun Kim; Gilwon Kang
Journal:  Medicina (Kaunas)       Date:  2021-11-24       Impact factor: 2.430

Review 10.  HDL Accessory Proteins in Parkinson's Disease-Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics-A Review.

Authors:  Izabela Berdowska; Małgorzata Matusiewicz; Małgorzata Krzystek-Korpacka
Journal:  Antioxidants (Basel)       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.